Cargando…

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban

AIMS: Atrial fibrillation ablation requires peri-procedural oral anticoagulation (OAC) to prevent thromboembolic events. There are several options for OAC. We evaluate peri-procedural AF ablation complications using a variety of peri-procedural OACs. METHODS AND RESULTS: We examined peri-procedural...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winkle, Roger A., Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Patrawala, Rob A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178475/ https://www.ncbi.nlm.nih.gov/pubmed/25115168 http://dx.doi.org/10.1093/europace/euu196

Ejemplares similares

Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes
por: Winkle, Roger A., et al.
Publicado: (2013)

Comparison of CHADS(2) and CHA(2)DS(2)-VAS(C) anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients
por: Winkle, Roger A., et al.
Publicado: (2014)

Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation
por: Winkle, Roger A., et al.
Publicado: (2012)

Trends in atrial fibrillation ablation: have we maximized the current paradigms?
por: Winkle, Roger A., et al.
Publicado: (2012)

Physician-controlled costs: the choice of equipment used for atrial fibrillation ablation
por: Winkle, Roger A., et al.
Publicado: (2013)

Atrial fibrillation ablation using very short duration 50 W ablations and contact force sensing catheters
por: Winkle, Roger A., et al.
Publicado: (2018)

Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
por: Pillarisetti, Jayasree, et al.
Publicado: (2020)

Ablation of atypical atrial flutters using ultra high density-activation sequence mapping
por: Winkle, Roger A., et al.
Publicado: (2016)

Internationally validated score to predict the outcome of non-paroxysmal atrial fibrillation ablation: the ‘FLAME score’
por: Boyalla, Vennela, et al.
Publicado: (2021)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study
por: Calkins, Hugh, et al.
Publicado: (2019)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

Catheter ablation for failed surgical maze: comparison of cut and sew vs. non-cut and sew maze
por: Winkle, Roger A., et al.
Publicado: (2019)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins
por: Jakimczuk, Aleksandra, et al.
Publicado: (2022)

Uninterrupted dabigatran is safer than warfarin in patients undergoing ablation for atrial fibrillation
por: Spartalis, Michael, et al.
Publicado: (2017)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures
por: Andrade, Marcus Vinicius Santos, et al.
Publicado: (2018)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

Atrial Fibrillation Ablation without Interruption of Anticoagulation
por: Santangeli, Pasquale, et al.
Publicado: (2011)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Effects of uninterrupted dabigatran on the intensity of anticoagulation during atrial fibrillation ablation
por: Osawa, Takumi, et al.
Publicado: (2021)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
por: Stolz, Leonie, et al.
Publicado: (2017)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
por: Lai, Chao‐Lun, et al.
Publicado: (2017)

Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial
por: Yoshida, Yukihiko, et al.
Publicado: (2018)

Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study
por: Hohnloser, Stefan H., et al.
Publicado: (2019)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
por: Yin, Lu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_35hm5n50e0fd7rul570qak16kj